QualityStocks today announces the production of stimulating videos featuring International Stem Cell Corp., providing insight to the exciting capabilities of stem cell research and the company’s revolutionary advances in the field of regenerative medicine.
The HD videos can be viewed at http://Video.QualityStocks.net
ISCO was the first to develop and perfect a new class of human stem cells created from unfertilized human eggs. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
Dr. Simon Craw, EVP of business development, in the videos details ISCO’s focus on using these “next-generation” stem cells to treat severe unmet medical needs of the central nervous system and beyond.
“Regenerative medicine has been called the next evolution of medical treatments by the U.S. Department of Health and Human Services. With its potential to heal, this new field of science is expected to revolutionize healthcare,” says Dr. Craw.
In mid-2014 ISCO plans to file with the U.S. Food and Drug Administration an investigational new drug (IND) application for Parkinson’s disease, a significant achievement that extends far beyond the company’s development.
“Filing the IND represents a big step forward for ISCO and a major advancement to the field of Parkinson’s disease research,” emphasizes Dr. Craw. “We have not only invested in our science but also in our manufacturing and have all the capacity we need to manufacture human cells and related products to support our strategic goals.”
Brett Lesser, VP of Sales for LifeLine Cell Technology, one of ISCO’s wholly-owned subsidiaries that specializes in manufacturing human cells, explains how ISCO’s cellular products are utilized by scientists searching for treatment of a number of other disease.
“Currently our cells are being used in experiments regarding lung cancer, breast cancer, prostate disease, COPD, asthma, diabetes, and a myriad of other life-threatening ailments,” states Lesser. “We’ve grown to a point where scientists from all over the world have published in some of the most prestigious scientific journals about advances in their own while using our cell culture products.”
The videos also describe ISCO’s self-sustaining business model, subsidiary business units, as well as provides insight on the company’s sweeping patent portfolio and investment opportunity.
Let us hear your thoughts: International Stem Cell Corp. Message Board
